Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermtech Inc (NQ: DMTK )

0.6301 +0.0007 (+0.11%)
Streaming Delayed Price Updated: 9:38 AM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dermtech Inc

< Previous 1 2 3 4 5 6 Next >
DermTech Reports First-Quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
New Survey Data Reveals Nearly 75% of Consumers Have Not Had a Full Skin Exam Within the Past 12 Months
From DermTech, Inc.
Via Business Wire
DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech, Inc. (NASDAQ:DMTK) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 04/19/2023 -- DermTech, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
DermTech Announces Release Date for First-quarter 2023 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Announces Contract With North Carolina Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
New Survey Finds Millennials and Gen Xers Not Following Safe Sun Habits, Increasing Risk of Nonmelanoma Skin Cancer
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech to Present at March Investor Conferences
From DermTech, Inc.
Via Business Wire
DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan
From DermTech, Inc.
Via Business Wire
DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test
From DermTech, Inc.
Via Business Wire
DermTech Reports Third-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Announces Release Date for Third-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook
From DermTech, Inc.
Via Business Wire
DermTech Appoints Chief Compliance Officer and SVP of Research and Development
From DermTech, Inc.
Via Business Wire
DermTech Announces Release Date for Second-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Appoints Two New Board Members
From DermTech, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.